Skip to content

Speeding the time-to-clinic with Optimer®

New research shows how Optimer can speed projects by up to 75% compared to standard antibodies. Speeding project timelines can be vital to the development of any life science product. Whether…

Oligo therapeutics vs ADCs. How do they stack up?

  Biologics, such as antibody therapeutics have revolutionised our approach to the treatment of disease. Therapeutic antibodies have become the predominant class of drugs in the development pipeline and the…